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Esophageal Fistula 
after EUS-FNA in a 
Patient Treated with 
Bevacizumab for  
Non–Small-Cell  
Lung Cancer
To the Editor:
A 54-year-old female patient is 
presented with a T1aN3M1b, epithelial 
growth factor receptor wild-type ade-
nocarcinoma originating in the right 
lung.
The patient was treated with four 
courses of carboplatin and paclitaxel 
combined with bevacizumab (15 mg/kg) 
followed by maintenance bevacizumab.
A partial remission was observed, 
persisting until after two courses of 
maintenance bevacizumab. At that 
moment, the patient exhibited a skin 
metastasis, but target lesions showed no 
progression and bevacizumab was con-
tinued. As there was a doubt whether 
the skin metastasis should be regarded 
as disease progression, further treat-
ment strategies were considered.
To exclude the presence of an 
EML–ALK gene reallocation, new sam-
ples were required as the original cell 
blocks were used up. A paraesophageal 
metastasis as easiest accessible lesion was 
approached with endoscopic ultrasound 
(EUS)–guided fine-needle aspiration.
A third and fourth bevacizumab 
course were administered 13 days 
before, respectively 8 days after EUS. 
Four weeks after EUS, a computed 
tomographic (CT) scan showed a new 
liver metastasis and increase of brain 
metastases indicating disease progres-
sion. Also a small air configuration in 
the sampled node was perceived.
In the meanwhile, the patient expe-
rienced mild, but gradually progressive 
retrosternal dyscomfort. Blood chemis-
try showed elevated C-reactive protein 
of 284 mg/liter. A CT scan (8 weeks 
after EUS) showed enlargement of the 
air space in the paraesophageal region. 
At esophagoscopy, an impression was 
observed with two elongated fissures 
covered with blood clots. At inspiration, 
air bubbles escaped from the fissures.
Tube feeding and antibiotics 
resulted in clinical and biochemical 
improvement of the patient.
A final CT scan (10 weeks after 
EUS) showed a progressive air space 
originating from the paraesophageal 
mass with access to the esophageal 
lumen (Figure).
In this patient, a fistula devel-
oped between a necrotizing medias-
tinal mass and the esophagus within 
4 weeks after EUS while on bevaci-
zumab treatment. Although cavitating 
mediastinal nodes were not described 
in particular previously, formation 
of bronchoesophageal fistula after 
bevacizumab was reported before, 
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Figure.  Computed tomography (CT) images showing a solid right paraesophageal 
lymph node metastasis after treatment with six courses of bevacizumab and 15 days 
before endoscopic ultrasound–guided fine-needle aspirations (EUS-FNA) (A). The 
same node 10 weeks after EUS-FNA and after eight courses of bevacizumab showing 
extensive cavitation and a breakthrough to the esophageal lumen (B).
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especially in patients pretreated with 
(chemo)radiotherapy.1,2
In this case, there seems to be a 
relationship between fistula formation 
and EUS. The high C-reactive protein, 
normalizing during antibiotic treatment, 
suggests an infectious component.
Normally, EUS-FNA is a safe 
technique but infectious mediastinitis 
in necrotic lymph nodes, resulting in 
cavitation, was reported previously.3
In our patient, optimal circum-
stances for fistula formation were created 
in the aspirated node by pretreatment 
with bevacizumab. repeated needle 
passes in necrotic tissue caused longitu-
dinal fissures. Delayed wound-healing 
and secondary infection resulted in fis-
tula formation finally.
EUS-FNA is therefore not recom-
mended in patients on treatment with 
bevacizumab. If EUS-FNA is nonethe-
less indicated, antibiotic prophylaxis is 
advisable.
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To the Editor:
I read with interest the article 
“highly Sensitive Detection of EGFR 
T790M Mutation Using Colony 
hybridization Predicts Favorable 
Prognosis of Patients with Lung Cancer 
harboring Activating EGFR Mutation” 
by Fujita et al.1 published in November 
2012 in this journal. The authors, using a 
highly sensitive methodology, detect, in 
pretyrosine kinase inhibitor (TKI) speci-
mens, a rate of EGFR T790M mutations 
of 79%, much higher than the rate of 0% 
to 35%, which was previously reported.2,3 
In addition, with a 0.5% cutoff of T790M 
pretreatment alleles, they find an asso-
ciation with favorable outcome. They 
suggest that the abundance of T790M 
mutated cells, and not their mere pres-
ence, is correlated with a better progno-
sis after TKI treatment. The biological 
paradox concerning how tumors carry-
ing two EGFR mutations with synergis-
tic oncogenic potential acquire slower 
growth kinetics, remains unexplained. 
Given the issue of tumor heterogeneity 
different scenarios can be speculated: 
(1), activating and resistant mutation 
in cis on the same allele, (2), in trans 
on different alleles and (3), in different 
clones. The first situation (Fig.1A), after 
TKI therapy, would lead to a decrease 
of sensitive target cells with an enrich-
ment of resistant double-mutated cells 
that, based on current biological evi-
dence, should be equipped with higher 
growth potential. In the second scenario 
(Fig.1B), tumor behavior would be dif-
ficult to anticipate, depending on which 
allele is expressed within the cells. The 
sensitive allele, however, should be 
preferentially expressed leading to an 
initial decrease of cells with the activat-
ing mutation and an increase of double-
mutated cells whose growth behavior, 
with the present knowledge, is unknown. 
In the last scenario (Fig.1C), where the 
mutations are present in different clones, 
selective drug pressure would be applied 
only on target cells with the activat-
ing mutation whereas the clones with 
the resistant T790M mutation would be 
advantaged to grow under drug pressure. 
This latter scenario could explain the 
more indolent behavior seen in patients 
with a pretreatment T790M mutation 
because the resistance mutation has been 
proven to be less oncogenic both in vitro 
and in vivo. The knowledge regarding 
the in cis or in trans position of the sen-
sitive and resistance mutations is cur-
rently scarce, and both possibilities have 
been reported. Kobayashi et al.4 with 
subcloning experiments found T790M 
mutations associated with both, exon 19 
deletions and wild-type sequences, sug-
gesting a monoallelic situation (in cis), 
possibly concomitant with a biallelic 
situation (in trans), or with the presence 
of distinct population of cells. Miyazawa 
et al.5 on the contrary, found only clones 
with single activating mutations or 
with both activating and resistant muta-
tions (in cis). In conclusion, the current 
knowledge on the evolution of resistance 
mutations is still scarce and, given the 
major clinical implications for the con-
tinous successful treatment Wof non–
small-cell lung cancer patients, deserves 
further study.
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